[1] Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies[J]. Clin Adv Hematol Oncol, 2010, 8(10): 705-718.
[2] NanaSinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer[J]. Transl Res, 2011, 157(4): 216-225.
[3] Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma[J]. Sarcoma, 2012, 2012: 359739.
[4] SitaLumsden A, Dart DA, Waxman J, et al. Circulating microRNAs as potential new biomarkers for prostate cancer [J]. Br J Cancer, 2013, 108(10): 1925-1930.
[5] Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma[J]. Cancer Res, 2002, 62(17): 4963-4967.
[6] HajAhmad TA, Abdalla MA, HajAhmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients[J]. J Cancer, 2014, 5(3): 182-191.
[7] Fassina A, Cappellesso R, Simonato F, et al. A 4MicroRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears[J]. Cancer Cytopathol, 2014, 122(4): 274-281.
[8] Fortunato O, Boeri M, Verri C, et al. Assessment of circulating microRNAs in plasma of lung cancer patients[J]. Molecules, 2014, 19(3): 3038-3054.
[9] Avissar M, Christensen BC, Kelsey KT, et al. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2009, 15(8): 2850-2855. |